WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Manal M.Younus*, Mohammed A.Taher, Jasim M. ALMaliki, Nawal M. AlKhalidi, Rawa w. Hussein


Background: Crohn’s disease (CD) and ulcerative colitis (UC) represent two distinct inflammatory bowel diseases (IBD), yet they share lots of similarities, both are idiopathic, progressive autoimmune diseases of unknown etiology, of a remitting and a reviving pattern with increasing incidence and prevalence all over the world. The introduction of infliximab in the treatment of both CD and UC patients had dramatically improves the disease activity and positively affects the quality of life. Selenium supplementation as antioxidant affect the inflamed bowel by changing the oxidative stress in the GIT environment and in this regard the combination of infliximab and selenium supplementation was studied to look for the effect of selenium supplementation on ADRs profile in IBD patients treated with infliximab. Patients and methods: A prospective interventional trial was conducted in the Gastroenterology and Hepatology specialized hospital, a tertiary center in Medical City Directorate in Baghdad, Iraq and patients were randomly assigned into 2 groups ,one received infliximab and the other group received infliximab plus selenium supplementation and patients were followed up for 3 consecutive visits every 8 weeks for 24 weeks after the baseline visit. Data were collected at each visit regarding ADRs in both groups and assessments were made accordingly. Results: Forty six patients were enrolled in this study divided into two groups each with twenty three patients, one group of patients were treated with infliximab and the other with infliximab plus selenium supplementation. The reported ADRs were infection (28.3%), anemia (6.5%) and skin reactions (6.5%). There was a non significant difference in the ADRs profile between the infliximab and selenium group, in spite of that anemia was not reported in the selenium group and there was a decrease in the total reported ADRs in the selenium group by (13%) when compared to infliximab group. Conclusion: Selenium may have a role in decreasing the number of reported ADRs when supplemented to IBD patients receiving infliximab.

Keywords: (ADRs) adverse drug reactions, (CD) Crohn's disease, (IBD) inflammatory bowel disease, (IFX) infliximab, (TNF) tumor necrosis factor,(UC) ulcerative colitis.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More